Endo International PLC (ENDPQ)

OTCMKTS: ENDPQ · Delayed Price · USD
0.129
-0.006 (-4.45%)
Sep 23, 2022 4:00 PM EDT - Market closed
-4.45%
Market Cap 30.31M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 235.14M
EPS (ttm) -3.11
PE Ratio n/a
Forward PE 1.52
Dividend n/a
Ex-Dividend Date n/a
Volume 1,910,776
Open 0.134
Previous Close 0.135
Day's Range 0.120 - 0.134
52-Week Range 0.092 - 0.230
Beta 1.15
Analysts n/a
Price Target 1.02 (+691.3%)
Earnings Date Nov 7, 2022

About ENDPQ

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PE... [Read more...]

Industry Pharmaceuticals
IPO Date Sep 25, 1996
Employees 3,103
Stock Exchange OTCMKTS
Ticker Symbol ENDPQ
Full Company Profile

Financial Performance

Financial Statements

News

Endo (ENDP) Files for Bankruptcy Amid Litigations, Huge Debt

Endo (ENDP) finally files for bankruptcy after negotiations with its debtholders as litigation claims continue to weigh on the business.

1 month ago - Zacks Investment Research

Weighed Down by Opioid Litigation, Endo International Files for Bankruptcy

The generic drugmaker faces thousands of lawsuits related to its alleged role in the opioid crisis.

1 month ago - Barrons

Percocet maker Endo International files for bankruptcy

Oxycodone maker Endo International files for bankruptcy and will put itself up for sale.

1 month ago - Fox Business

Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and...

Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants Patients and Customers Will ...

1 month ago - PRNewsWire

Endo International (ENDP) Stock Plunges Amid Bankruptcy Warning

It hasn't been a good run for Endo International (NASDAQ: ENDP ), and Tuesday isn't making it any better. Shares of ENDP stock are down more than 40% today and almost 60% from last week's high.

1 month ago - InvestorPlace

Endo International (ENDP) Tops Q2 Earnings and Revenue Estimates

Endo (ENDP) delivered earnings and revenue surprises of 118.75% and 9.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

New Drug Filing for Cenobamate Accepted for Review in Canada and Israel

SK Biopharmaceuticals is eligible to receive milestones for future approval and commercialization in Canada and Israel PANGYO, South Korea , Aug. 9, 2022 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd....

1 month ago - PRNewsWire

ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS

DUBLIN , Aug. 9, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2022. SECOND-QUARTER FINANCIAL PERFORMANCE (in thousand...

1 month ago - PRNewsWire

Buxton Helmsley Issues Letter to Endo International Plc. Directors, Relating to Financial Disclosures

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with financial inte...

1 month ago - Business Wire

Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada

Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.

2 months ago - Zacks Investment Research

Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN , July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiar...

Other symbols: QNRX
2 months ago - PRNewsWire

Why Is Endo International (ENDP) Stock Up Today?

After a week of roller-coaster price action, ENDP stock is on the upswing even after Endo International posts disappointing clinical results. The post Why Is Endo International (ENDP) Stock Up Today?

2 months ago - InvestorPlace

Endo (ENDP) Phase II Study for Frozen Shoulder Disappoints

Endo (ENDP) mid-stage study of collagenase clostridium histolyticum (or CCH) for treating frozen shoulder disappoints.

2 months ago - Zacks Investment Research

Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor

DUBLIN , July 1, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company's subsidiaries Endo P...

2 months ago - PRNewsWire

Why Endo International Shares Are Getting Hammered Today

Endo International PLC (NASDAQ: ENDP) shares are trading lower by 16.86% to $0.39 after the company provided top-line results from its Phase 2 study of CCH in patients with adhesive capsulitis of the sh...

2 months ago - Benzinga

Endo Posts Disappointing Data From Frozen Shoulder Trial

Endo International plc (NASDAQ: ENDP) has announced topline results from its Phase 2 study of collagenase clostridium histolyticum (CCH) in participants with adhesive capsulitis (AC) of the shoulder (fr...

2 months ago - Benzinga

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with ...

DUBLIN , July 1, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced top-line results from its Phase 2 study of Collagenase Clostridium Histolyticum (or "CCH") in participants wit...

2 months ago - PRNewsWire

Endo International (ENDP) Stock Plunges 20% After Missing Interest Payment

Here's what investors may want to know about today's 20% downside move in ENDO stock, a day after this stock rocketed 90% higher. The post Endo International (ENDP) Stock Plunges 20% After Missing Inter...

2 months ago - InvestorPlace

Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?

Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.

2 months ago - Zacks Investment Research

Energy Stocks: An Investment Guide

Investing in energy can be a key part of your portfolio. This guide will help you invest in oil, natural gas and renewable energy stocks.

2 months ago - InvestorPlace

What Is a Stock Split and How Does It Work?

At the end of the day, stock splits are a matter of simple arithmetic. Here's a closer look at what you should know about stock splits.

Other symbols: AMZNLYTSHOP
2 months ago - InvestorPlace

Why Is Endo International (ENDP) Stock Up 90% Today?

Endo International has been surging all day but it isn't just Plan B that has kept it rising. Here's why ENDP stock is a name to watch.

2 months ago - InvestorPlace

Endo (ENDP) Inks Deal for Osteoarthritis Knee Pain Drug

Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.

3 months ago - Zacks Investment Research

Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee...

DUBLIN , June 13, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) has executed an agreement with Taiwan Liposome Company, Ltd. ...

3 months ago - PRNewsWire

Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt

Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.

4 months ago - Zacks Investment Research